secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001437749-23-030944
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic Q3 revenue $397K (-55% YoY); cash $8.2M; Phase 1 top-line results expected Dec 2023
--------------------------------------------------------------------------------

- Revenue $397K vs $880K YoY; net loss $1.614M ($0.06) vs $1.809M ($0.06).
- Cash $8.2M as of Sep 30, down from $12.7M at Dec 31, 2022.
- Received $0.6M upfront in Oct for Dapibus animal-free dairy enzyme license.
- DYAI-100 Phase 1 top-line results expected Dec 2023; no major safety concerns.
- New collaboration with Mass General/DoD ($5.88M grant) and bYoRNA for mRNA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774923030944/0001437749-23-030944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774923030944/dyai20230825_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-030944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer